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S u m m a r y Peripheral blood tnononuclear cells (PBMC) were taken by Ieukapheresis from a patient with
meUinoma skin metastasesaticlstimulated in v'/niuising lOOO 111 recombinant interleukin 2 (II.-2)/ml
t(i generate lymphokitiL'-activated killer ceils iI.AK cells), Two-colour imtnunoiluorescence analysis
demonstrated an lL-2-induced up-regulation ot'CD25 on natural killer cells (CD5()* I as well as on T
lymphocytes ICD5 ^  ). After radiolabelling w ith indium-111. the cells were reinfused. Gamma-camera
imaging revealed an enrichment at the tumour sites. Immunostaining of tumour tissue taken before
and after scintigraphy demonstrated CD2 5* T lymphocytes (CD2*. CD3'^  1. but no natural killer cells
(CDKi'. CD56 ' ) infiltrating the metastases.
I,AK cell enrichmeut at melaiiotna metastases in vivo did not involve natural killer cells, but was
characterized by increased numbers of activated T lymphocytes in this patient.
Interleukin 2 (IL-21 was originally designated T-cell
growth factor* because of its ability to tnaintain long-
term in v((n)cultures of T lymphocytes.' It augments the
cytotoxic activity of natural killer cells and cytotoxic T
cells against a variety of cultured and fresh tumour cells.
This enhanced cytotoxicity after brief exposure ot periph-
eral blood mononuclear cells (PBIVIC) to IL-2 is referred
to as lymphokine-activated killer (LAKl cell activity.-
"LAK' does not define a certain cell type, but a functional
property which is exerted by a mixture of different cell
types.' ^
Rccetitly. we reported the successful imaging of
melanoma metastases usitig radiolabelled I.,AK cells,""
The co-operation of a patient with metastatic malignant
melanoma allowed us to take sequential biopsies to
characterize the trafficking cells during LAK cell scinti-
graphy.
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Methods
Patient
A S2-year-old man. suffering irom tnelanoma. with
multiple skin and lymph-node metastases. gave written
informed consent to LAK cell scintigraphy according to a
protocol approved by the Ethical Committee of the
University of Wiirzburg. He allowed biopsies to be taken
from a skin metastasis before, and 120 h after, scinti-
graphy. Half of each specimen was snap-frozen, and the
other half fixed with buffered formalin, embedded in
paraffin, and stained with haematoxylin and eosin.
Generation of LAK activity
Peripheral blood mononuclear cells (PBIUC) were col-
lected by a 3-h Ieukapheresis (Haemonetics V 50). After
Eicoll-Hypaque centrifugation. I^ BMC were cultured in
plastic bags (Ijfecell culture bags 1000 ml. Fenwall
containing KPMI Ki4{) tnedium ((Jibco. Germany),
supplemented with 2% human serum, antibiotics, and
1 ()()() It; recombinant interleukin 2 (Proleukin. Euroce-
tus. Frankfurt) for 4 days.
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Imwwwjliiorcscence anahisis
Immediately after collection and prior to reinfusion.
PBMC were analysed using monoclonal antibodies CD i.
CD56, CD25 {Becton Dickinson. San Jose. CA. U.S.A.).
They were washed twice with PBS. and then incubated
with purified human IgG for 10 min to inhibit sub-
sequent monoclonal antibody binding to immunoglu-
bufin receptors. Cells (1 x 10*') were incubated for 30
min with a first-step antibody. After two washes with
HBSS containing 0 2% sodium azide. cells were stained
for 50 min with FabS goat anti-mouse Tg(^  FITC
conjugate. After two washes, the cells were incubated for
20 min with excess mouse IgG to block free goat anti-
mouse lg(i-binding sites. The goat anti-mouse IgG and
blocking steps were omitted for samples stained with
directly FITC-conjugated monoclonal antibodies. After
the blocking step, directly PE-conjugated monoclonal
antibody was added, followed 30 min later hy two
washes. All incubations and washes were performed at
4°C. Ceils were analysed with a EACScan (Becton
Dickinson) at 488 and 590 nm. The noise threshold was
set to exclude volume signals below those of lympho-
cytes. Ail analyses were performed using photomulti-
plier voltages and gain settings that were standardized
using tluorescent calibration beads, and all signals were
processed using logarithmic amplification. Fluoro-
chrome-conjugated mouse IgG2a monoclonal antibody
controls were used to assess the degree of non specific
antibody binding to each cell preparation.
CR-^l release assaij
Cytotoxic activity of the PBMC was determined in a
standard 4-h CR-51 release assay as previously de-
scribed.' using the erythroblastoma cell line K Shi and
the B lymphoblastoid line Raji as target cells. Effector/
target ratios were 40:1 and 10:1. Spontaneous release
was assessed by incubating labelled K Sf-)2 in medium
alone, and total release was evaluated by a solution of
sodium dodecyl sulphate. After the supernatants were
harvested using a Skatron filter-stick system, radio-
activity was measured in a Pharmacia gamma-counter.
Specific lysis (SL) was calculated as:
Mean experimental release —mean spontaneous release
Mean total release —mean spontaneous release
X 100
LAK cell scintiijraphii
After the 4-day, high dose rL-2 stimulation. PBMC were
washed twice and incubated with 7 • 5 MBq indium-11 i
oxine in 4 ml PBS for 1 5 min at 37°Cin an atmosphere of
5% COj in air. After labelling, viability was assessed by
trypan blue dye exclusion. PBMC {1 x lO**) were trans-
ferred into 250 ml normal saline and reinfused within
JO min using a standard blood tubing set containing a
200 ^m in-line filter. Static gamma-camera imaging was
obtained 2 5. 24. 48. 9(S and 120 h after transfusion.
Inuuunostaininfi of skin biopsies
Snap-frozen biopsy specimens were stored at - 70°C
until use. They were stained by the APAAP technique.^
using a panel of monoclonal antibodies. Three hundred
mononuclear cells were counted (magnification x 400)
and the percentage of stained lymphoid mononuclear
cells was scored semiquantitatively (Table 1).
Results
Generatiou of LAK cells
The incubation of 1 5 x lO"^  PBMC with 1000 IU IL-2/mi
for 4 days had no detectable infiuence on the absolute
cell number. Viability prior to. and after, the incubation
period was >95%.
Inuuiinofhiorcsccuce analifsis
The two-colour immunofluorescence analysis using
antibodies against CD25. CD3. and CDS6 showed an
augmented expression of CD25 on CD3*^  as well as
CDSfi' cells (Fig. 1).
Table 1. Phcnolypinsi of Ihe pt-rittimoral inliltrate in biop.sics prior to.
and al'lLT. LAK-ccI! scintigraphy (0. none positive: -^. I - S % positive;
I -^. T-2S% posilivL': -f + + . 25-SO% positive: +-^--1-. > S0%
positive peritumoriil mononuck 'ar ccllsl
CL) cluster
CD2
C'Di
f lH
CDS
CD Id
Cl)5h
Cl)2^
Predominant
reactivity
T lymph(K7tes
T lymphocytes
T helper
T suppressor
NK-cells
NK-cells
IL-2 receplor
Peritumoral inliltrate
Prior to LAK
scintigraphy
+ + + +
+ + + +
+ + + +
-I- +
(1
0
1)
After LAK
scintigraphy
+ + + +
+ + + +
+ + + +
+ +
(I
0
+ +
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Before After
CD2?i
ligure 1. Two-ailour FACS analysis
demonstnitt's im iiicrfiisc of CD2 5 expression
on T lyinphucyte (CD i ' I as well iis on NK-
cells (CDS6'") after 4 days' inriibatii>n with
1 ()()() III IL-2. The numbers in the corners
indicate the percentage of cells. The numbers
in the right upper corners indicate the
percentage of dimblf-posilivc cells.
CD25
64
7 >V 14
CD25
24
32
CD56 CD56
30
t'K-5 / release assat/
The incubciti<m of PBMC with 1 ()()() Hi IL-2/ml resulted
in an enhancement of cytotoxicity from 4 V7 to 57- 3%
SL for an effector/target ratio of 10:1 using the NK cell
target K S62. Basic SL of Raji cells was 1 7 9 % (effector/
target ratio 40:1) and 4-9% (effector/target ratio 10:1).
After lL-2 incubation. SL increased to 40 2% (effector/
target ratio 40:1) and 21-4% (effector/target ratio
10:1).
LAK cell scintiijraplm
After a 4-day cuiture in the presence of IL-2, 1 0 x 10"*
cells were labelled with 7- 5 MBq. Prior to reinfusion. the
cells gained an activity of SfS MBq (lahelling efficacy
75%, viability >95%). The infusion of the radiolabelled
cells was well tolerated. Transient fever (maximum
J8-5°C) did not require specilic treatment. Reinfused
cells migrated primarily to the lungs, liver and spleen
(2-S h after reinfusion}. Alter 24 h, the liver and spleen
showed a slight increase in activity, whereas the amount
of activity in the lutigs decreased. After 48 h, multiple
lymph-node and subcutaneous localization was demon-
strated, corresponding well to tumour sites detected by
CT-scan. One-hundred and twenty hours post-infusion,
radioactivity was still clearly present in the metastases
(Fig. 2).
Immunostaining of skin biopsies
The biopsies taken prior to therapy and from a scinti-
graphically positive skin metastasis 120 h after reinfu-
sion of radiolabelled LAK cells were both stained with a
panel of monoclonal antibodies (Table 1). Because the
reactive cells accumulate in clusters around the tumour
tissue, it was impossible to qtiantify the lymphocytes in
both biopsies. 'I'here was no qualitative change in the
distribution of cells. However, an increase of CD2 5
expression was observed in representative fields. In
addition, the tumour cells expressed intercellular ad-
hesion molecule-1 and HLA-DR.
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l - i g u r c 2 . T i i i n o i i r l o t ' i i l i z a t i o n o l d t i u ' l d s i i i l i f l u r i i D u r ( I ' l i n t h e l o w t - r
i i l i d o m c n s h o w n o n t h t - C T s c i i n I a l a n d b y s c i n l i M . ' < i n i b a n d c ) , i b ) w a s
laken 24 h, iind k'l 1 211 h after reinfusion otnid ioi a belled LAK-fclls, Ib)
shows activity in the liver (LI, spleen (Si. spine, and tumour tissues (T),
In (I'l, the liver and spleen have cleared, hut there is still activity al the
lumoiir sites (T).
Discussion
The clinical application of interleukin 2 in inimiino-
therapy resulted in new approaches for adoptive cell
transfer using I.AK cells,"* A (adherent) LAK cells,"
tumour-infiltrating lymphocytes,^ and tumour-acti-
vated lymphocytes.'' Immunotherapies using inter-
leukin 2 are capable of inducing tumour regression.
However, the mechanisms still remain unclear. The
uugmentiition of cell-mediated cytotoxicity is thought to
be a major effect of II,,-2 administration in vivo, but it is
imdear whether cytotoxic cells are able to migrate to
tumour sites, and which cytotoxic cell types are involved
in this cellular traffic.
Although some studies have failed to demonstrate
aggregation of radiolabelled lAK cells in metastatic
cancer,'" or have shown only poor enrichment at the
tumour sites in comparison with tumour antigen-sensi-
tized killer cells," LAK cell homing without additional
infusion of IL-2 was recently demonstrated in metastatic
melanoma.''
As LAK cells consist of a heterogeneous mixture of
different cell types which are defined by their functional
ability to lyse NK-resistant target cells, WL- tried to
ascertain which cell population includes the migrating
cells. A co-operative patient with extensive sktn meta-
stases gave us the unique opportunity to study the
cellular traffic in vivo.
The stimulation of this patient's PBMC induced aug-
mented lytic activity against the NK-sensitive target cell
line K 5h2. and against NK resistant Raji cells. Two-
colour immunofluorescencc analysis revealed an
increased expression of CD25 (low-affinity IL-2 receptor)
on CD5* T lymphocytes as well as CD5f)^  natural killer
cells,'- ' ^  demonstrating the activated status of these cell
types.
After radiolabelling with indium-Ill (half-life 2-8
days) and reinfusion into the patient via a peripheral
vein, we observed the common cellular traffic, with
aggregation of cells in the lungs, liver and spleen.
Localization in the tumour metastases also occurred,
detectable 48 h post-infusion, and still present after 120
h. At this latter time-point, radioactivity had cleared
from the liver, lungs and spleen.
ln skin biopsies taken from scintigraphically docu-
mented LAK cell infiltrated tissue, we were not able to
detect CD56^ cells. No qualitative change in the peri-
tumoral infiltrate was found in this tissue. The only
significant change was an increase of CD25 expression.
These findings suggest an influx of activated T lympho-
cytes, and might depend on conformation a I changes of
the leucocyte function antigen (LFA-1) molecule asso-
ciated with the activation.'^ However, because LHA-1 is
expressed by virtually all leucocytes, including T lym-
phocytes and NK cells.'' it remains unclear why no
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CD5(i' NK ceils were found in the skin biopsies. One
explanation could be a sequestration of NK cells in the
lungs.'^' This would correspond well with reports about
aggregation of natural killer cells in a regressing
pulmonary metastasis, induced by IL-2 administration
and intravenous LAK cell transfer via a central line.' '
and effective immunotherapy using LAK-application
into the hepatic artery in a patient with HLA-DK liver
melanoma metastases.'"^ In both cases LAK-cell therapy
induced tumour regression in uii adjacent organ directly
reachable by the transfused cells without relevant
dilution. Therefore, the adoptive cell transfer in both
cases can be interpreted as a locoregional treatment.
With regard to the regression of metastases during
systemic IL-2 therapy plus adoptive cell transfer. ;i
positive correlation was found between T lymphocyte
infiltrate, HLA-DR expression and response.'"* HLA-DK
expression seems to be an important precondition for
IL-2-induced tumour regression. In our patient, the
melanoma cells expressed HLA-DR as well as intercellu-
lar adhesion molecule-1, Possibly, these molecules were
involved in the accumulation of transferred T cells in this
particular patient.
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